|
1
|
Wilson TA, Karajannis MA and Harter DH:
Glioblastoma multiforme: State of the art and future therapeutics.
Surg Neurol Int. 5:642014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hart MG, Garside R, Rogers G, Stein K and
Grant R: Temozolomide for high grade glioma. Cochrane Database Syst
Rev. 4:CD0074152013.PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hau P, Koch D, Hundsberger T, Marg E,
Bauer B, Rudolph R, Rauch M, Brenner A, Rieckmann P, Schuth J, et
al: Safety and feasibility of long-term temozolomide treatment in
patients with high-grade glioma. Neurology. 68:688–690. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
do Carmo A, Balça-Silva J, Matias D and
Lopes MC: PKC signaling in glioblastoma. Cancer Biol Ther.
14:287–294. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan QW and Weiss WA: Targeting the
RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr
Top Microbiol Immunol. 347:279–296. 2010.PubMed/NCBI
|
|
9
|
Luwor RB, Stylli SS and Kaye AH: The role
of Stat3 in glioblastoma multiforme. J Clin Neurosci. 20:907–911.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kohsaka S, Wang L, Yachi K, Mahabir R,
Narita T, Itoh T, Tanino M, Kimura T, Nishihara H and Tanaka S:
STAT3 inhibition overcomes temozolomide resistance in glioblastoma
by downregulating MGMT expression. Mol Cancer Ther. 11:1289–1299.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fabbri M: MicroRNAs and cancer: towards a
personalized medicine. Curr Mol Med. 13:751–756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Williams AE: Functional aspects of animal
microRNAs. Cell Mol Life Sci. 65:545–562. 2008. View Article : Google Scholar
|
|
13
|
Wang S, Li Q, Wang K, Dai Y, Yang J, Xue
S, Han F, Zhang Q, Liu J and Wu W: Decreased expression of
microRNA-31 associates with aggressive tumor progression and poor
prognosis in patients with bladder cancer. Clin Transl Oncol.
15:849–854. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Asangani IA, Harms PW, Dodson L, Pandhi M,
Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy
N and Chinnaiyan AM: Genetic and epigenetic loss of microRNA-31
leads to feed-forward expression of EZH2 in melanoma. Oncotarget.
3:1011–1025. 2012.PubMed/NCBI
|
|
15
|
Nosho K, Igarashi H, Nojima M, Ito M,
Maruyama R, Yoshii S, Naito T, Sukawa Y, Mikami M, Sumioka W, et
al: Association of microRNA-31 with BRAF mutation, colorectal
cancer survival and serrated pathway. Carcinogenesis. 35:776–783.
2014. View Article : Google Scholar
|
|
16
|
Wang S, Jiao B, Geng S, Song J, Liang Z
and Lu S: Concomitant microRNA-31 downregulation and radixin
upregulation predicts advanced tumor progression and unfavorable
prognosis in patients with gliomas. J Neurol Sci. 338:71–76. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li T, Luo W, Liu K, Lv X and Xi T: miR-31
promotes proliferation of colon cancer cells by targeting E2F2.
Biotechnol Lett. 37:523–532. 2015. View Article : Google Scholar
|
|
18
|
Huang S, Wu B, Li D, Zhou W, Deng G, Zhang
K and Li Y: Knockdown of astrocyte elevated gene-1 inhibits tumor
growth and modifies microRNAs expression profiles in human
colorectal cancer cells. Biochem Biophys Res Commun. 444:338–345.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
20
|
Pilati C, Amessou M, Bihl MP, Balabaud C,
Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G,
et al: Somatic mutations activating STAT3 in human inflammatory
hepatocellular adenomas. J Exp Med. 208:1359–1366. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Filippi-Chiela EC, Thomé MP, Bueno e Silva
MM, Pelegrini AL, Ledur PF, Garicochea B, Zamin LL and Lenz G:
Resveratrol abrogates the temozolomide-induced G2 arrest leading to
mitotic catastrophe and reinforces the temozolomide-induced
senescence in glioma cells. BMC Cancer. 13:1472013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen L, Wang X, Wang H, Li Y, Yan W, Han
L, Zhang K, Zhang J, Wang Y, Feng Y, et al: miR-137 is frequently
downregulated in glioblastoma and is a negative regulator of Cox-2.
Eur J Cancer. 48:3104–3111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q
and Tao R: MicroRNA-205 functions as a tumor suppressor in human
glioblastoma cells by targeting VEGF-A. Oncol Rep. 27:1200–1206.
2012.
|
|
24
|
Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ,
Yao Q, Zhou H and Qu LH: MicroRNA-195 plays a tumor-suppressor role
in human glioblastoma cells by targeting signaling pathways
involved in cellular proliferation and invasion. Neuro Oncol.
14:278–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Körner C, Keklikoglou I, Bender C, Wörner
A, Münstermann E and Wiemann S: MicroRNA-31 sensitizes human breast
cells to apoptosis by direct targeting of protein kinase C epsilon
(PKCepsilon). J Biol Chem. 288:8750–8761. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mitamura T, Watari H, Wang L, Kanno H,
Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S
and Sakuragi N: microRNA 31 functions as an endometrial cancer
oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer.
13:972014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar
|
|
28
|
McFarland BC, Hong SW, Rajbhandari R,
Twitty GB Jr, Gray GK, Yu H, Benveniste EN and Nozell SE:
NF-κB-induced IL-6 ensures STAT3 activation and tumor
aggressiveness in glioblastoma. PLoS One. 8:e787282013. View Article : Google Scholar
|
|
29
|
Swiatek-Machado K, Mieczkowski J,
Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S,
Szeja W, Grynkiewicz G, Lesyng B, et al: Novel small molecular
inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and
exhibit a potent antitumor activity in glioma cells. Cancer Biol
Ther. 13:657–670. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Wang Q, Cui Y, Liu ZY, Zhao W,
Wang CL, Dong Y, Hou L, Hu G, Luo C, et al: Knockdown of cyclin D1
inhibits proliferation, induces apoptosis, and attenuates the
invasive capacity of human glioblastoma cells. J Neurooncol.
106:473–484. 2012. View Article : Google Scholar
|
|
31
|
Premkumar DR, Jane EP, Foster KA and
Pollack IF: Survivin inhibitor YM-155 sensitizes tumor necrosis
factor- related apoptosis-inducing ligand-resistant glioma cells to
apoptosis through Mcl-1 downregulation and by engaging the
mitochondrial death pathway. J Pharmacol Exp Ther. 346:201–210.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lo HW, Cao X, Zhu H and Ali-Osman F:
Constitutively activated STAT3 frequently coexpresses with
epidermal growth factor receptor in high-grade gliomas and
targeting STAT3 sensitizes them to Iressa and alkylators. Clin
Cancer Res. 14:6042–6054. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mitamura T, Watari H, Wang L, Kanno H,
Hassan MK, Miyazaki M, Katoh Y, Kimura T, Tanino M, Nishihara H, et
al: Downregulation of miRNA-31 induces taxane resistance in ovarian
cancer cells through increase of receptor tyrosine kinase MET.
Oncogenesis. 2:e402013. View Article : Google Scholar : PubMed/NCBI
|
